Eli Lilly and Co is to enter the therapeutic arena for psychedelic medicines with the acquisition of AtaiBeckley Inc of New York City, US, giving it ownership of clinical-stage products for treatment-resistant depression and social anxiety disorder. Announced on 16 July, the deal involves an upfront cash payment of $2.8 billion. There would also be an additional $1 billion due by Lilly to the seller if certain development and regulatory milestones are met.
